Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $270.1 million.

  • Zevra Therapeutics' Liabilities and Shareholders Equity rose 4101.52% to $270.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $877.2 million, marking a year-over-year increase of 3300.02%. This contributed to the annual value of $178.1 million for FY2024, which is 336.57% up from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Liabilities and Shareholders Equity is $270.1 million, which was up 4101.52% from $256.3 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Liabilities and Shareholders Equity ranged from a high of $270.1 million in Q3 2025 and a low of $90.4 million during Q1 2021
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $138.8 million (2021), whereas its average is $151.2 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 112443.77% in 2021, then plummeted by 1520.29% in 2023.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Liabilities and Shareholders Equity stood at $132.9 million in 2021, then fell by 13.24% to $115.3 million in 2022, then soared by 49.41% to $172.3 million in 2023, then increased by 3.37% to $178.1 million in 2024, then soared by 51.64% to $270.1 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $270.1 million for Q3 2025, versus $256.3 million for Q2 2025 and $172.7 million for Q1 2025.